dismiss

Our Clean Sweep Live Auction is coming up fast! Next Tuesday, September 26th at 9:30AM EST

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
当前地点:
>
> This Story


注册记数器 to rate this News Story
Forward Printable StoryPrint Comment

 

Business Affairs Homepage

Jonathan Isaacs TBWA\WorldHealth hire chief creative officer

Alan Baron Proton Partners International appoints New Board Member

Cardiologist salaries are on the rise in the U.S., survey finds Growing faster on the private side

Radiology Partners to acquire Southwest Diagnostic Imaging Joining with SDI 'represents about a 25 percent increase' in RP's size

Alpha Imaging acquires Medical Imaging Systems Will provide services to customers in 16 states

Invicro acquires Imanova Creating the world’s largest provider of translational imaging services

Resilience Capital Partners acquires three medical device service and manufacturing companies Forms Innovatus Imaging Corporation

Mazor Robotics and Medtronic enter next phase of strategic partnership Medtronic to make a $40 million investment

Dr. Michael A. DeVita EarlySense appoints first chief medical officer

For Philips, Asia-Pacific is filled with opportunity Number of people over age 60 in region projected to hit 1.3 billion by 2050

Philips to enhance therapeutic offerings via dual acquisitions

By John R. Fischer

Royal Philips is in the process of acquiring Spectranetics Corporation and recently completed the acquisition of CardioProlific Inc. as part of a plan to combine its image-guided therapy technology with devices that provide therapeutic treatments for peripheral vascular disease and other serious conditions.

Incorporating the capabilities of these companies will enable Philips to offer its imaging technology to identify and confirm treatments, as well as catheter-based products developed by Spectranetics and CardioProlific to administer those treatments in minimally-invasive procedures.

Story Continues Below Advertisement

Connecting Vitals Acquisition at the Point of Care

Vital signs acquisition happens countless times a day, but disconnected processes and devices for gathering measurements leave a lot of room for improvement. See how a connected ecosystem helps improve accuracy and efficiency. Click to learn more>



“We have a better solution for our customers to not only guide them during the procedure with imaging and decide, based on intravascular imaging, but also treat these patients better, and then have a proclamation on whether they got the right treatment again with imaging,” said Bert Van Meurs, the business leader for the Image-Guided Therapy Business Group at Philips.

Peripheral vascular disease refers to the narrowing of blood vessels outside the heart and brain that creates blockages that prevent the flow of blood to the limbs through arteries and veins. If left untreated, it can lead to amputations of fingers, toes and limbs as well as strokes, heart attacks or death.

Spectranetics, which specializes in areas of vascular intervention and lead management, has developed devices for tackling peripheral vascular disease and other conditions, such as the extraction of pacemaker leads, cardiovascular disease and coronary artery disease. Its portfolio includes a variety of laser atherectomy catheters for eliminating and reducing blockages in coronary and peripheral arteries; the AngioSculpt scoring balloon that mechanically pushes aside substances that create blockage; Stellarex drug-coated balloons that help prevent blockage from recurring and treat different types of lesions; and AngioSculptX, the only drug-coated scoring balloon on the market. Philips purchased the company for €1.9 billion with the agreement to be finalized in the third quarter of this year.

“We really see it as a complimentary fit where our imaging portfolio really has a strong fit with their therapeutic devices portfolio, not only for peripheral vascular, but also coronary artery disease and EP [Electrophysiology],” said Van Meurs.

The financial details were not disclosed for CardioProlific, a private startup that is creating catheter-based thrombectomy technology for treating peripheral vascular disease by removing clots from arteries and veins. Philips plans to develop the technology alongside the company.

Philips previously purchased Volcano Corporation, which develops catheter-based imaging and measurement solution products, in late 2014 for $1.2 billion to enhance its imaging technology. Following the acquisition of CardioProlific and Spectranetics, employees from both companies will join Philips’ Image-Guided Therapy Business Group, which is called Philips Volcano.

Van Meurs says that the combination of imaging and catheter-based therapeutic solution devices will allow doctors to address problems in patients faster, while potentially reducing recovery periods, hospital stay times and costs for health care systems.

“Our customers, interventional cardiologists or interventional radiologists, are really looking at having the best treatment for the patient, and therefore, we are looking at these procedures and seeing how we can innovate,” said Van Meurs.

Business Affairs Homepage


You Must Be Logged In To Post A Comment

做广告
提升您的品牌知名度
拍卖+私人销售
获得最好的价格
买设备/配件
找到最低价格
每日新闻
阅读最新信息
目录
浏览所有的DOTmed用户
DOTmed上的伦理
查看我们的伦理计划
金子分开供营商节目
接收PH要求
金子服务经销商节目
接收请求
提供保健服务者
查看所有的HCP(简称医疗保健提供商)的工具
工作/训练
查找/申请工作
Parts Hunter +EasyPay
获取配件报价
最近证明
查看最近通过认证的用户
最近额定
查看最近通过认证的用户
出租中央
租用设备优惠
卖设备/配件
得到最划算
服务技术员论坛
查找帮助和建议
简单的征求建议书
获取设备报价
真正商业展览
查找对设备的服务
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对 DOTmed.com,公司 Copyright ©2001-2017 DOTmed.com, Inc.
版权所有